The global cell line development market size is expected to reach USD 10.09 billion by 2030 and is expected to expand at a CAGR of 9.81% from 2023 to 2030, according to a new report by Grand View Research, Inc. One of the primary factors driving the expansion of the cell line development (CLD) market is an increase in vaccine production around the world, especially after the spread of coronavirus. Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market. The expansion and growth of the biologics sector will also be a major CLD market development determinant.
The increasing product launches of technologically improved products for CLD are likely to drive market expansion. For example, CYTENA, a BICO subsidiary, introduced a new platform for entirely automated stable cell line development in October 2021. To enable cost-effective and better laboratory automation, the system integrates CYTENA's best-in-class liquid handling information with its existing established single-cell dispensing technology. BICO's Bio Convergence agenda is advanced through the broadening of accessibility to the advancement of next-generation medical services such as antibody treatments, gene therapies, and biosimilar production.
Moreover, according to the July 2021 Pharma Manufacturing Updates, approximately 20 drugs, comprising a few blockbusters including Novartis' Entresto & Biogen's Spinraza, are going to have their patents scheduled to expire in 2023. The expiration of branded pharmaceuticals has resulted in the creation of biosimilars. As a result, the requirement for cell line development is increasing. Thus, it will drive the market growth.
Furthermore, the growing company strategies such as collaboration, expansion, and acquisitions are also driving the market growth. For instance, ProBioGen and Granite Bio collaborated in July 2022 to provide GMP manufacturing & cell line development solutions and support Granite Bio's mAb pipeline development. Similarly, in June 2022, FUJIFILM Corporation announced a USD 1.6 billion investment to improve and expand the cell culture production capabilities of FUJIFILM Diosynth Biotechnologies. Furthermore, in October 2022, Cytiva, acquired CEVEC Pharmaceuticals, a prominent German producer of advanced CLD & viral vector manufacturing technology. Through this development, CEVEC will help Cytiva maintain its leadership position in biomanufacturing technologies.
However, the high capital expenses and expenditure needed to construct research and development capabilities would be a barrier to the cell line development industry.
Request a free sample copy or view report summary: Cell Line Development Market Report
By product, the reagents and media segment accounted for the largest share of 43.78% in 2022. Due to their cost-intensive nature and frequent use in the manufacturing of biologics, these items account for the biggest revenue share.
By source, the mammalian cell line segment accounted for the largest share of 72.62% in 2022.Its rapid expansion is a result of the effective manufacture of biopharmaceuticals by mammalian cell lines, as they are able to express complex proteins that are identical to those found in humans.
By type of cell line, the recombinant cell lines companies segment accounted for the largest share of 31.79% in 2022 due to its widespread application in biologics manufacturing processes, gene activation, including protein interactions.
By application, the bioproduction segment held the largest market share of 46.30% in 2022. Factors such as increased in-vitro research activities, product safety and efficacy concerns, the demand for biosimilars, and rising demand for cellular therapies are driving the bioproduction industry.
North America held the larger share of 39.22% in 2022 due to the presence of constant technological improvements followed by new discoveries sparking the adoption of newer processes for bioproduction. The presence of rigorous activities carried out by research businesses operating in this region, such as Thermo Fisher Scientific Inc., Sigma-Aldrich Corporation, and American Type Culture Collection (ATCC), which provide high-quality CLD services, is contributing to growth.
A few of the key market players of the market include Thermo Fisher Scientific Inc., Corning Inc., Lonza, Creative BioLabs., WuXi PharmaTech, Sartorius AG, Merck KGaA, Advanced Instruments, Berkeley Lights, Danaher among others.
Grand view research has segmented the global cell line development market based on product & services, source, type of cell lines, application and region:
Cell Line Development Product & Services Outlook (Revenue, USD Million, 2018 - 2030)
Reagents and media
Equipment
Automated Systems
Centrifuges
Bioreactors
Storage equipment
Others
Services
Accessories and consumables
Cell Line Development Source Outlook (Revenue, USD Million, 2018 - 2030)
Mammalian cell line
Non-mammalian cell line
Insects
Amphibians
Cell Line Development Type of Cell Lines Outlook (Revenue, USD Million, 2018 - 2030)
Recombinant cell lines
Hybridomas
Continuous cell lines
Primary cell lines
Cell Line Development Application Outlook (Revenue, USD Million, 2018 - 2030)
Bioproduction
Drug discovery
Toxicity testing
Tissue engineering
Others
Cell Line Development Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Cell Line Development Market
Thermo Fisher Scientific Inc.
Danaher
Sartorius AG
Merck KGaACorning Inc.
Lonza
Creative BioLabs.
WuXi PharmaTech
Advanced Instruments
Berkeley Lights
"The quality of research they have done for us has been excellent..."